Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.0620 USD
−52.15 M USD
0.00 USD
55.85 M
About Aptose Biosciences, Inc.
Sector
CEO
William G. Rice
Headquarters
Toronto
Website
Founded
1986
FIGI
BBG000F3TXC9
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Aptos Biosciences APTO - Testing critical supportThis level should provide substantial support for a possible bounce. The risk/reward here is favorable for a long. Stop loss is essential, as always.
APTO Technical Analysis 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
APTO Technical Analysis 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
APTO Technical Analysis. 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of APTO is 0.2790 USD — it has decreased by −4.81% in the past 24 hours. Watch Aptose Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aptose Biosciences, Inc. stocks are traded under the ticker APTO.
APTO stock has fallen by −6.23% compared to the previous week, the month change is a −49.94% fall, over the last year Aptose Biosciences, Inc. has showed a −88.03% decrease.
We've gathered analysts' opinions on Aptose Biosciences, Inc. future price: according to them, APTO price has a max estimate of 2.00 USD and a min estimate of 2.00 USD. Watch APTO chart and read a more detailed Aptose Biosciences, Inc. stock forecast: see what analysts think of Aptose Biosciences, Inc. and suggest that you do with its stocks.
APTO reached its all-time high on Mar 6, 2000 with the price of 33,071.6859 USD, and its all-time low was 0.1300 USD and was reached on Nov 22, 2024. View more price dynamics on APTO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
APTO stock is 104.13% volatile and has beta coefficient of −0.65. Track Aptose Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aptose Biosciences, Inc. there?
Today Aptose Biosciences, Inc. has the market capitalization of 17.35 M, it has increased by 0.84% over the last week.
Yes, you can track Aptose Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Aptose Biosciences, Inc. is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
APTO earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.64 USD resulting in a 42.19% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Aptose Biosciences, Inc. earnings.
Aptose Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
APTO net income for the last quarter is −7.01 M USD, while the quarter before that showed −7.25 M USD of net income which accounts for 3.33% change. Track more Aptose Biosciences, Inc. financial stats to get the full picture.
No, APTO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 35.00 employees. See our rating of the largest employees — is Aptose Biosciences, Inc. on this list?
Like other stocks, APTO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aptose Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aptose Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aptose Biosciences, Inc. stock shows the sell signal. See more of Aptose Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.